EA201792376A3 - Молекулы анти-gcc антитела и соответствующие композиции и способы - Google Patents

Молекулы анти-gcc антитела и соответствующие композиции и способы

Info

Publication number
EA201792376A3
EA201792376A3 EA201792376A EA201792376A EA201792376A3 EA 201792376 A3 EA201792376 A3 EA 201792376A3 EA 201792376 A EA201792376 A EA 201792376A EA 201792376 A EA201792376 A EA 201792376A EA 201792376 A3 EA201792376 A3 EA 201792376A3
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
gcc
antigen
methods
related compositions
Prior art date
Application number
EA201792376A
Other languages
English (en)
Other versions
EA201792376A2 (ru
Inventor
Самьюэл С. Нам
Эдвард А. Гринфилд
Джон Бабкук
Тереза О'Киф
Шисинь Цин
Original Assignee
Милленниум Фармасьютикалз, Инк.
Эмджен Бритиш Коламбиа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк., Эмджен Бритиш Коламбиа filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201792376A2 publication Critical patent/EA201792376A2/ru
Publication of EA201792376A3 publication Critical patent/EA201792376A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Описаны антитела и антигенсвязывающие фрагменты антител, которые связывают GCC. Антитела связывают внеклеточный домен GCC и могут интернализоваться. В некоторых вариантах осуществления антитела являются гуманизированными, химерными или человеческими. Также описаны нуклеиновые кислоты и векторы, кодирующие антитела или их части, рекомбинантные клетки, которые содержат нуклеиновые кислоты, и композиции, содержащие антитела или антигенсвязывающие фрагменты. Изобретение также обеспечивает терапевтические и диагностические способы с использованием антител и антигенсвязывающих фрагментов, раскрытых в настоящей заявке.
EA201792376A 2009-10-23 2010-10-22 Молекулы анти-gcc антитела и соответствующие композиции и способы EA201792376A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25447409P 2009-10-23 2009-10-23

Publications (2)

Publication Number Publication Date
EA201792376A2 EA201792376A2 (ru) 2018-03-30
EA201792376A3 true EA201792376A3 (ru) 2018-08-31

Family

ID=43900696

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201270365A EA030827B1 (ru) 2009-10-23 2010-10-22 Анти-gcc антитело и его применения
EA201792376A EA201792376A3 (ru) 2009-10-23 2010-10-22 Молекулы анти-gcc антитела и соответствующие композиции и способы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201270365A EA030827B1 (ru) 2009-10-23 2010-10-22 Анти-gcc антитело и его применения

Country Status (32)

Country Link
US (3) US8785600B2 (ru)
EP (2) EP3520816B1 (ru)
JP (2) JP5925684B2 (ru)
KR (2) KR101834890B1 (ru)
CN (3) CN104447996A (ru)
AR (1) AR078751A1 (ru)
AU (1) AU2010310545C1 (ru)
BR (1) BR112012007523A2 (ru)
CA (2) CA2774032C (ru)
CL (1) CL2012000806A1 (ru)
CR (1) CR20120124A (ru)
DO (1) DOP2012000066A (ru)
EA (2) EA030827B1 (ru)
EC (1) ECSP12011761A (ru)
ES (1) ES2788457T3 (ru)
GE (2) GEP20166504B (ru)
IL (3) IL218763A (ru)
IN (1) IN2012DN02604A (ru)
MA (1) MA33601B1 (ru)
MX (3) MX2012003198A (ru)
MY (1) MY173390A (ru)
NZ (2) NZ623607A (ru)
PE (1) PE20121542A1 (ru)
PH (1) PH12019500438A1 (ru)
PL (1) PL2490720T3 (ru)
SA (1) SA110310795B1 (ru)
SG (3) SG10202011656XA (ru)
TN (1) TN2012000122A1 (ru)
TW (2) TWI583394B (ru)
UA (1) UA108991C2 (ru)
WO (1) WO2011050242A1 (ru)
ZA (1) ZA201201944B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
IN2012DN02604A (ru) 2009-10-23 2015-09-04 Millennium Pharm Inc
SG181563A1 (en) * 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
KR101844479B1 (ko) 2011-11-17 2018-04-03 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
MY176695A (en) 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
PE20142322A1 (es) * 2012-04-27 2015-01-25 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
CN105142664A (zh) * 2013-02-28 2015-12-09 米伦纽姆医药公司 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症
MY183572A (en) * 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
JP2015209384A (ja) * 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 医薬製剤
BR112018015917A2 (pt) * 2016-02-05 2018-12-26 Immunogen Inc conjugados de anticorpos-fármaco direcionados a gcc
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN109219445B (zh) 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
KR101928079B1 (ko) 2016-12-12 2018-12-11 한화케미칼 주식회사 디시클로펜타디엔계 수지의 제조 방법 및 디시클로펜타디엔계 수지
CN108452318B (zh) * 2017-02-17 2023-05-26 浙江特瑞思药业股份有限公司 靶向cd20的抗体偶联药物及其制备方法和用途
CN108452319A (zh) * 2017-02-20 2018-08-28 浙江特瑞思药业股份有限公司 靶向cd20的抗体偶联药物制剂
CA3093705A1 (en) * 2018-03-16 2019-09-19 Thomas Jefferson University Anti-gucy2c chimeric antigen receptor compositions and methods
EP3796983A2 (en) * 2018-05-23 2021-03-31 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
JP2022532192A (ja) 2019-05-10 2022-07-13 武田薬品工業株式会社 抗体薬物複合体
EP4045532A4 (en) * 2019-10-14 2024-02-28 Scripps Research Inst LARGELY NEUTRALIZING HUMAN ANTIBODIES AGAINST HIV ENV PROXIMAL-EXTERNAL MEMBRANE REGION FOR VACCINE DESIGN AND INTERVENTION
AU2020475819A1 (en) * 2019-11-07 2022-06-23 Thomas Jefferson University Anti-GUCY2C vaccines and vaccination
WO2021205325A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
US20210371492A1 (en) * 2020-06-02 2021-12-02 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC Antibody and CAR thereof for Treating Digestive System Cancer
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
WO2022216079A1 (ko) * 2021-04-07 2022-10-13 주식회사 엘지화학 Gucy2c 결합 폴리펩타이드 및 그의 용도
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
WO2024067762A1 (en) * 2022-09-28 2024-04-04 Nanjing Legend Biotech Co., Ltd. Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35500A (en) 1862-06-10 Improvement in dampers
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
ES2125854T3 (es) 1989-08-09 1999-03-16 Rhomed Inc Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5237051A (en) * 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1993016043A1 (en) 1992-02-18 1993-08-19 Otsuka Kagaku Kabushiki Kaisha β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CA2174928C (en) 1993-10-26 2011-08-16 Scott A. Waldman Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
WO1997042506A1 (en) 1996-05-03 1997-11-13 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
DE69723580T2 (de) 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6340463B1 (en) 1996-08-14 2002-01-22 Vanderbilt University Identification of antigenic peptide sequences
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
GB9700154D0 (en) 1997-01-07 1997-02-26 Primapharma Ltd Peptides
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
AU768295B2 (en) 1998-11-03 2003-12-04 Centocor Inc. Modified antibodies and antibody fragments with increased duration of activity
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6132922A (en) 1999-01-06 2000-10-17 Advanced Color Technology, Inc. Liquid developer for electrophotographic printing apparatus
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
AU5870800A (en) * 1999-06-09 2000-12-28 Ljl Biosystems, Inc. Cell-signaling assays
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
FR2805994A1 (fr) 2000-03-10 2001-09-14 Agronomique Inst Nat Rech Methode de detection de la guanylyl cyclase-c et son utilisation pour le diagnostic des tumeurs colorectales metastatiques
DE60140865D1 (de) * 2000-03-27 2010-02-04 Univ Jefferson Zusammensetzungen und methoden zur identifizierung von krebszellen
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002256985B8 (en) * 2001-01-26 2008-03-20 Inhibitex, Inc Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
EP2944648B1 (en) 2001-03-29 2019-11-13 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for the treatment of organ inflammation
EP1451211A2 (en) 2001-03-30 2004-09-01 University of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
YU80903A (sh) * 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003057838A2 (en) * 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20030186302A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003272511A1 (en) * 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
AU2004239065B2 (en) * 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
BRPI0411852A (pt) * 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
CA2559870A1 (en) 2004-04-07 2005-10-27 Genetech,Inc. Mass spectrometry of antibody conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1781339B1 (en) 2004-06-25 2013-12-25 Thomas Jefferson University Guanylyl cyclase C ligands
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
AU2005319382B2 (en) * 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ME00977B (me) * 2007-08-10 2012-06-20 Regeneron Pharma Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta
CA2696011A1 (en) 2007-08-10 2009-02-19 Centocor Ortho Biotech Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
HUE031533T2 (hu) 2007-10-19 2017-07-28 Seattle Genetics Inc CD19-kötõszerek valamint alkalmazásuk
WO2009067800A1 (en) 2007-11-27 2009-06-04 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof
CN102016579B (zh) 2007-11-30 2015-04-08 健泰科生物技术公司 Vegf多态性和抗血管发生疗法
US20110195415A1 (en) 2008-05-13 2011-08-11 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
WO2009149278A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
WO2010096929A1 (en) 2009-02-25 2010-09-02 Diagnocure Inc. Method for detecting metastasis of gi cancer
EP2407786A4 (en) 2009-03-12 2013-01-02 Univ Kinki METHOD FOR PREDICTING THE THERAPEUTIC EFFICACY OF CHEMOTHERAPY ON NON-SMALL CELL LUNG CANCER
CA2801729A1 (en) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions for and methods of activating guanylyl cyclase c
EP2491116A4 (en) 2009-10-22 2013-12-11 Univ Jefferson CELL-BASED ANTI-RISK COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
IN2012DN02604A (ru) 2009-10-23 2015-09-04 Millennium Pharm Inc
JP2013534515A (ja) 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
EP2603239A2 (en) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Neuropilin as a biomarker for bevacizumab combination therapies
WO2013016662A1 (en) * 2011-07-28 2013-01-31 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
PE20142322A1 (es) 2012-04-27 2015-01-25 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
CN105142664A (zh) 2013-02-28 2015-12-09 米伦纽姆医药公司 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症
US20160303258A1 (en) 2013-12-03 2016-10-20 Millennium Pharmaceuticals, Inc. Compounds and compositions for imaging gcc-expressing cells
BR112018015917A2 (pt) 2016-02-05 2018-12-26 Immunogen Inc conjugados de anticorpos-fármaco direcionados a gcc
CN109219445B (zh) 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用

Also Published As

Publication number Publication date
MA33601B1 (fr) 2012-09-01
AU2010310545A8 (en) 2012-10-11
AR078751A1 (es) 2011-11-30
AU2010310545A1 (en) 2012-05-17
EA030827B1 (ru) 2018-10-31
PL2490720T3 (pl) 2020-08-24
US20140322233A1 (en) 2014-10-30
CA3031851A1 (en) 2011-04-28
KR20120128120A (ko) 2012-11-26
TN2012000122A1 (en) 2013-09-19
SA110310795B1 (ar) 2014-07-14
EA201270365A1 (ru) 2012-09-28
TW201132352A (en) 2011-10-01
IL247842B (en) 2018-06-28
EP2490720A1 (en) 2012-08-29
NZ623607A (en) 2016-07-29
PE20121542A1 (es) 2012-12-06
MX366890B (es) 2019-07-30
MX2019008956A (es) 2019-09-13
SG179567A1 (en) 2012-05-30
EP3520816B1 (en) 2022-08-31
CN110054692A (zh) 2019-07-26
US8785600B2 (en) 2014-07-22
IL260285B (en) 2019-08-29
UA108991C2 (uk) 2015-07-10
DOP2012000066A (es) 2013-04-15
KR20170123723A (ko) 2017-11-08
PH12019500438A1 (en) 2020-07-20
EP3520816A3 (en) 2019-10-09
IL218763A0 (en) 2012-06-28
KR101834890B1 (ko) 2018-04-20
SG10202011656XA (en) 2020-12-30
BR112012007523A2 (pt) 2017-06-20
CN102573908B (zh) 2014-12-17
US20180355062A1 (en) 2018-12-13
CN102573908A (zh) 2012-07-11
IL218763A (en) 2016-10-31
GEP20166504B (en) 2016-06-27
SG10201407757XA (en) 2015-01-29
MY173390A (en) 2020-01-22
JP5925684B2 (ja) 2016-05-25
EA201792376A2 (ru) 2018-03-30
JP2013507968A (ja) 2013-03-07
US20110110936A1 (en) 2011-05-12
CL2012000806A1 (es) 2012-08-03
GEP20196956B (en) 2019-03-25
TWI583394B (zh) 2017-05-21
CA2774032C (en) 2019-03-26
MX2012003198A (es) 2012-06-12
ECSP12011761A (es) 2012-05-30
AU2010310545B2 (en) 2014-11-06
TWI483736B (zh) 2015-05-11
CN104447996A (zh) 2015-03-25
AU2010310545C1 (en) 2015-04-30
TW201524517A (zh) 2015-07-01
ZA201201944B (en) 2013-05-29
EP2490720B1 (en) 2020-02-12
US10941211B2 (en) 2021-03-09
ES2788457T3 (es) 2020-10-21
IL260285A (en) 2018-07-31
NZ598791A (en) 2014-05-30
IN2012DN02604A (ru) 2015-09-04
EP2490720A4 (en) 2013-06-05
CA2774032A1 (en) 2011-04-28
WO2011050242A1 (en) 2011-04-28
CA3031851C (en) 2020-07-07
JP2016028603A (ja) 2016-03-03
CR20120124A (es) 2012-07-04
EP3520816A2 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
WO2006104677A3 (en) Antibodies that bind ov064 and methods of use therefor
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EA201100923A1 (ru) Антитела человека против тканевого фактора
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201492149A1 (ru) St2-антигенсвязывающие белки
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
SG160248A1 (en) Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
EA202090278A1 (ru) Антигенсвязывающие области против доменов фибронектина типа iii и способы их применения
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
SG10201909377XA (en) Antibodies that bind human cd27 and uses thereof
UA109423C2 (uk) Композиція та спосіб для діагностики і лікування пухлини